Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo nabs $150M to in-li­cense more as­sets

Athena Coun­tou­ri­o­tis and her team at Aven­zo Ther­a­peu­tics have reeled in an ad­di­tion­al $150 mil­lion just two and a half months af­ter in-li­cens­ing their first clin­i­cal-stage as­set.

With the Se­ries A-1, the biotech has now raised $347 mil­lion in to­tal fi­nanc­ing since its Au­gust 2022 in­cep­tion, Aven­zo told End­points News Tues­day morn­ing. That makes it one of the largest Se­ries A fi­nanc­ings in re­cent biotech mem­o­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER